Detalles de la búsqueda
1.
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.
Lancet
; 402(10396): 118-128, 2023 07 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37331368
2.
Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings.
Am Heart J
; 270: 55-61, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38266665
3.
Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia.
Am Heart J
; 253: 20-29, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35728658
4.
Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study.
J Am Heart Assoc
; 12(19): e028227, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37753718
5.
Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201).
Circ Arrhythm Electrophysiol
; 16(12): 639-650, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37950726
6.
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).
Circ Arrhythm Electrophysiol
; 15(12): e010915, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36441560
Resultados
1 -
6
de 6
1
Próxima >
>>